Chiaojung Jillian Tsai, Lead of the Allan and Ruth Kerbel Palliative Radiotherapy and Oligometastasis Program at Princess Margaret Cancer Centre, shared Cristiane D. Bergerot’s, Former Postdoc Fellow and Research Consultant at City of Hope, post on X:
“Thanks Cristiane D. Bergerot for the mention. The Canadian Cancer Trials Group needs everyone’s support to answer this crucial question.”
Quoting Cristiane D. Bergerot’s post:
“CURB2 will determine whether targeting oligoprogression with SBRT can extend the benefit of first-line ICI-based therapy.”
Title: CCTG BR38: Randomized Phase III Trial of Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Non–Small Cell Lung Cancer
Authors: C. Jillian Tsai, Alexander Sun, Penelope A. Bradbury, Devin Schellenberg, Houda Bahig, Andrea S. Fung, Jean-Pierre Bissonnette, Jeeban P. Das, Biniam Kidane, Alexander V. Louie, Joseph A. Miccio, Meng Xu-Welliver, John Varlotto, Arya Amini, Ryan Kelly, Keyue Ding and Pierre-OlivierGaudreau.
Read the full article here.
Read more articles featuring Chiaojung Jillian Tsai on OncoDaily.